Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Impact of Metamizole on Anti-Xa Concentrations in Oncology Patients Receiving DOACs
NCT07384013Recruiting
- Sponsor
- Rambam Health Care Campus
- Start
- Nov 2025
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of Metamizole sodium in pain (2 cohorts), sponsored by Rambam Health Care Campus. Primary endpoint: Change in DOAC Anti-Xa Concentrations. Started Nov 2025; status: recruiting.
02
Drugs
Metamizole sodium
03
Conditions
pain
Beyond the preview
Go deeper on NCT07384013.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07384013.